Amphastar Pharmaceuticals公司(纳斯达克代码:AMPH)2024年第四季度财报业绩不佳,触发其在盘后交易中大幅下跌10.19%。
根据公司公布的最新财报,Amphastar 2024年第四季度调整后每股收益为0.92美元,低于分析师预期的0.94美元。季度销售额达1.865亿美元,也未能达到预期的1.888亿美元目标。
公司每股收益和营收均未达预期,引发市场对其盈利能力和增长前景的质疑。分析人士指出,该公司可能面临来自仿制药竞争加剧、新药研发进展缓慢、或营运成本过高等挑战。投资者对Amphastar的长期发展潜力失去信心,从而导致股价在盘后交易中大幅下挫。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.